China Resources Pharmaceutical Group Ltd. (640) Ratios
China Resources Pharmaceutical Group Ltd. Ratios
DE:640's free cash flow for Q2 2026 was $-946.59M. For the 2026 fiscal year, DE:640's free cash flow was decreased by $-1.79B and operating cash flow was $847.32M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.42 | 1.41 | 1.33 | 1.25 | 1.25 |
| Quick Ratio | 1.11 | 1.13 | 1.09 | 1.03 | 1.04 |
| Cash Ratio | 0.11 | 0.12 | 0.18 | 0.18 | 0.18 |
| Solvency Ratio | 0.05 | 0.04 | 0.04 | 0.04 | 0.04 |
| Operating Cash Flow Ratio | 0.14 | 0.12 | 0.12 | 0.08 | 0.08 |
| Short-Term Operating Cash Flow Coverage | 0.28 | 0.37 | 0.34 | 0.21 | 0.19 |
| Net Current Asset Value | $ 37.15B | $ 27.85B | $ 9.37B | $ 20.22B | $ 23.92B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.33 | 0.27 | 0.23 | 0.26 | 0.27 |
| Debt-to-Equity Ratio | 1.83 | 1.43 | 1.23 | 1.29 | 1.33 |
| Debt-to-Capital Ratio | 0.65 | 0.59 | 0.55 | 0.56 | 0.57 |
| Long-Term Debt-to-Capital Ratio | 0.29 | 0.32 | 0.23 | 0.17 | 0.12 |
| Financial Leverage Ratio | 5.56 | 5.34 | 5.37 | 4.92 | 4.88 |
| Debt Service Coverage Ratio | 0.20 | 0.26 | 0.28 | 0.24 | 0.16 |
| Interest Coverage Ratio | 6.33 | 5.65 | 4.88 | 3.79 | 3.41 |
| Debt to Market Cap | 3.72 | 2.01 | 1.89 | 1.57 | 2.98 |
| Interest Debt Per Share | 17.04 | 12.05 | 10.27 | 10.62 | 11.25 |
| Net Debt to EBITDA | 4.70 | 3.62 | 2.43 | 2.57 | 3.57 |
| Profitability Margins | |||||
| Gross Profit Margin | 16.51% | 15.79% | 15.60% | 15.40% | 14.94% |
| EBIT Margin | 4.69% | 4.65% | 4.54% | 4.85% | 3.85% |
| EBITDA Margin | 6.18% | 5.64% | 5.71% | 6.09% | 5.04% |
| Operating Profit Margin | 4.63% | 4.70% | 4.31% | 4.26% | 3.91% |
| Pretax Profit Margin | 4.38% | 4.24% | 4.02% | 3.88% | 3.55% |
| Net Profit Margin | 1.50% | 1.30% | 1.43% | 1.38% | 1.30% |
| Continuous Operations Profit Margin | 3.58% | 3.26% | 3.16% | 3.09% | 2.81% |
| Net Income Per EBT | 34.30% | 30.66% | 35.46% | 35.52% | 36.64% |
| EBT Per EBIT | 94.43% | 90.17% | 93.25% | 91.15% | 90.91% |
| Return on Assets (ROA) | 1.41% | 1.30% | 1.42% | 1.43% | 1.24% |
| Return on Equity (ROE) | 7.86% | 6.95% | 7.62% | 7.06% | 6.04% |
| Return on Capital Employed (ROCE) | 8.69% | 9.66% | 8.49% | 10.05% | 8.62% |
| Return on Invested Capital (ROIC) | 4.73% | 5.45% | 5.68% | 5.46% | 4.38% |
| Return on Tangible Assets | 1.62% | 1.47% | 1.59% | 1.84% | 1.62% |
| Earnings Yield | 16.10% | 9.96% | 11.96% | 8.82% | 13.81% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.65 | 2.53 | 3.27 | 2.48 | 3.57 |
| Payables Turnover | 5.25 | 5.42 | 4.17 | 4.41 | 3.26 |
| Inventory Turnover | 5.20 | 5.86 | 7.12 | 7.23 | 6.78 |
| Fixed Asset Turnover | 8.31 | 10.41 | 9.68 | 10.27 | 9.27 |
| Asset Turnover | 0.94 | 1.00 | 1.00 | 1.04 | 0.95 |
| Working Capital Turnover Ratio | 4.87 | 5.41 | 6.89 | 7.32 | 7.92 |
| Cash Conversion Cycle | 138.47 | 138.95 | 75.19 | 115.15 | 44.19 |
| Days of Sales Outstanding | 137.76 | 144.02 | 111.48 | 147.40 | 102.32 |
| Days of Inventory Outstanding | 70.23 | 62.33 | 51.25 | 50.46 | 53.80 |
| Days of Payables Outstanding | 69.52 | 67.40 | 87.54 | 82.71 | 111.92 |
| Operating Cycle | 207.99 | 206.35 | 162.73 | 197.86 | 156.11 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.63 | 2.79 | 2.48 | 1.73 | 1.79 |
| Free Cash Flow Per Share | 3.00 | 2.32 | 1.98 | 1.20 | 1.32 |
| Dividend Paid and CapEx Coverage Ratio | 4.73 | 3.80 | 3.79 | 2.54 | 3.07 |
| Capital Expenditure Coverage Ratio | 5.77 | 5.85 | 4.96 | 3.25 | 3.87 |
| Operating Cash Flow Coverage Ratio | 0.22 | 0.24 | 0.25 | 0.17 | 0.17 |
| Operating Cash Flow to Sales Ratio | 0.08 | 0.06 | 0.06 | 0.04 | 0.05 |
| Free Cash Flow Yield | 67.36% | 40.62% | 38.53% | 19.00% | 37.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.18 | 10.04 | 8.36 | 11.34 | 7.24 |
| Price-to-Sales (P/S) Ratio | 0.09 | 0.13 | 0.12 | 0.16 | 0.09 |
| Price-to-Book (P/B) Ratio | 0.49 | 0.70 | 0.64 | 0.80 | 0.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 1.48 | 2.46 | 2.60 | 5.26 | 2.68 |
| Price-to-Operating Cash Flow Ratio | 1.23 | 2.04 | 2.07 | 3.64 | 1.99 |
| Price-to-Earnings Growth (PEG) Ratio | 0.22 | -0.57 | 2.76 | 1.13 | 0.47 |
| Enterprise Value Multiple | 6.21 | 5.94 | 4.52 | 5.13 | 5.44 |
| Enterprise Value | 115.20B | 91.76B | 69.74B | 79.44B | 64.93B |
| EV to EBITDA | 6.21 | 5.94 | 4.52 | 5.13 | 5.44 |
| EV to Sales | 0.38 | 0.33 | 0.26 | 0.31 | 0.27 |
| EV to Free Cash Flow | 6.12 | 6.31 | 5.62 | 10.53 | 7.81 |
| EV to Operating Cash Flow | 5.06 | 5.23 | 4.48 | 7.29 | 5.79 |
| Tangible Book Value Per Share | 14.52 | 11.69 | 11.59 | 6.29 | 5.88 |
| Shareholders’ Equity Per Share | 9.11 | 8.17 | 8.05 | 7.89 | 8.11 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.18 | 0.23 | 0.19 | 0.20 | 0.21 |
| Revenue Per Share | 47.75 | 43.64 | 43.04 | 40.45 | 37.69 |
| Net Income Per Share | 0.72 | 0.57 | 0.61 | 0.56 | 0.49 |
| Tax Burden | 0.34 | 0.31 | 0.35 | 0.36 | 0.37 |
| Interest Burden | 0.93 | 0.91 | 0.89 | 0.80 | 0.92 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| SG&A to Revenue | 0.11 | 0.10 | 0.03 | 0.02 | 0.03 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.74 | 4.83 | 1.57 | 2.63 | 2.98 |
Currency in CNY